FDA Approves Moderna’s mRNA RSV Vaccine For Older Adults

Reuters (5/31, Wingrove) reported the FDA “approved Moderna’s respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.” The vaccination “was approved for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 or older, but with a label indicating the shot was 79% effective at preventing at least two symptoms of RSV, such as cough and fever,” even though the company “had filed for FDA approval in July on data from a late-stage trial that showed its vaccine was 84% effective at preventing those symptoms.” The Hill (5/31, Choi) reported, “The approval makes RSV the second disease for which an mRNA vaccine has been greenlighted. There are two other RSV vaccines approved for adults older than 60: Arexvy by GSK and Abrysvo by Pfizer. Moderna’s mRESVIA is now the third shot added to the arsenal against RSV.” CNN (5/31, Christensen) also reported.